Elanco Acquires Bayer AG’s Animal Health Business

The transaction creates the second-largest animal health products company and will double Elanco’s companion animal business, advancing the company’s intentional portfolio mix transformation and creating a balance between its food animal and companion animal segments, the company said.
 

Elanco expects the combined organization to continue to deliver mid-single digit revenue growth, while accelerating achievement of adjusted gross margin goals and delivering double digit adjusted EBITDA margin growth.

“Joining Elanco and Bayer Animal Health strengthens and accelerates our IPP strategy, transforms our portfolio with the addition of well-known pet brands, brings an increased presence in key emerging markets, expands innovation, and accelerates our margin expansion journey,” Jeffrey N. Simmons, President and CEO of Elanco, said.

Philippi Prietocarrizosa Ferrero DU & Uría (PPU) acted as Colombian counsel to US company Elanco Animal Health. PPU’s team advising Elanco was led by partner Diego Cardona (pictured), with associates Federica del Llano and Natalia Castilla.